Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VRTX vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRTX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

VRTX Overall Winner 6-Pillar Tally: VRTX 4 – 2 MRNA Matrix Metrics: VRTX 6 – 4 MRNA

As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

  • Growth vs. Quality Trade-Off: VRTX earns the overall head-to-head edge with a stronger Unified Composite Score (40.9/100 SELL vs. MRNA 40.3/100 SELL) and 0.35β · 28% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both VRTX (40.9/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRTX vs MRNA
VRTX NASDAQ Head-to-Head Winner
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$515.02
-1.08% 1D
Market Cap $132.0B
TTM Revenue $13.0B
Forward P/E 25.9x
Beta / 30D Vol 0.35β · 28% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.0%) with fading momentum, RSI 41
RSI-14: 40.9 · SMA20: $538.04 · SMA50: $522.73
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (VRTX 4 – 2 MRNA)

Columns: Metric · VRTX · MRNA
1. Valuation Multiples MRNA
Forward P/E 25.9x 23.0x
Trailing P/E 33.5x 23.0x
PEG Ratio 2.34x N/M
EV / Revenue 10.3x 33.1x
2. Growth & Scale VRTX
Revenue Growth (YoY) +11.8% +29.2%
Earnings Growth (YoY) -39.0% -85.1%
TTM Revenue (USD) $13.0B $2.52B
Market Cap $132.0B $80.7B
3. Profitability & Quality VRTX
Gross Margin 54.8% -42.0%
Operating Margin 37.8% -80.8%
Net Profit Margin 30.7% -110.5%
Return on Equity (ROE) 20.8% -34.5%
4. Balance Sheet & Cash Flow VRTX
Cash Generation (TTM) $3.20B -$2.04B
Cash Flow Margin 24.7% -81.0%
Net Cash / Leverage $1.50B Net Debt (0.31x D/E) $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRTX
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 115.6% (33rd %ile) 89.6% (52nd %ile)
Put/Call OI Skew 1.00x (Balanced) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Distribution DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 17.0% of Rev ($2.20B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRTX (6) vs MRNA (4)
Institutional Metric VRTX MRNA Criterion Row Edge
Market Capitalization
Scale
$132.0B $80.7B Larger Scale VRTX
Trailing P/E Ratio
Valuation
33.5x 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
25.9x 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+11.8% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
37.8% -80.8% Higher Margin VRTX
Net Profit Margin
Profitability
30.7% -110.5% Higher Margin VRTX
Return on Equity (ROE)
Capital Efficiency
20.8% -34.5% Higher ROE VRTX
52-Week Range Position
Momentum
66% ($412–$569) 67% ($22–$281) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
0.35β · 28% Vol 2.23β · 78% Vol Lower Realized Risk VRTX
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite VRTX
Trailing 12M Revenue (USD)
Operating Scale
$13.0B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.8% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.34x PEG · 10.3x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.20B ($1.50B Net Debt (0.31x D/E)) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon Tie
VRTX: -3.77% · MRNA: -3.77%
3M Horizon MRNA +46.35 pp
VRTX: -5.95% · MRNA: +40.4%
6M Horizon MRNA +297.43 pp
VRTX: +18.53% · MRNA: +315.96%
1Y Horizon MRNA +684.13 pp
VRTX: +22.32% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VRTX Revenue MRNA Revenue VRTX Op. Margin MRNA Op. Margin Margin Leader
FY2018 $3.05B $140M 20.8% -306.0% VRTX
FY2019 $4.16B $60M 28.8% -906.8% VRTX
FY2020 $6.21B $800M 46.0% -95.0% VRTX
FY2021 $7.57B $18.5B 36.7% 72.0% MRNA
FY2022 $8.93B $19.3B 48.2% 48.9% MRNA
FY2023 $9.87B $6.85B 38.8% -61.9% VRTX
FY2024 $11.0B $3.24B -2.1% -121.9% VRTX
FY2025 $12.0B $1.94B 34.8% -158.1% VRTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRTX CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 115.6%
IV Percentile 33rd %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VRTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $537.79 · IV 35.9%

VRTX vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of VRTX ($53,779) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

VRTX Spot $537.79 · IV 35.9%
VRTX Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $540 / $570 Bull Call Spread

Buy 1x $540C · Sell 1x $570C · 31d

Net Entry $1,114 Debit
T+5d @ +5% Move +$591 (+53%)
Max Risk / Buffer $1,114 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $500 / $470 Bull Put Spread

Sell 1x $500P · Buy 1x $470P · 31d

Net Entry $545 Credit
Max Credit / Yield +$545 (+22.2% RoM)
Max Risk / Buffer -8.0% Cushion ($2,455 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $132.0B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($2.20B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ VRTX vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: VRTX earns the overall head-to-head edge with a stronger Unified Composite Score (40.9/100 SELL vs. MRNA 40.3/100 SELL) and 0.35β · 28% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both VRTX (40.9/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRTX leads the Growth & Scale pillar: VRTX posts +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VRTX cumulative revenue shifted +293.4% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, VRTX deploys 17.0% of Rev ($2.20B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. VRTX trades at 25.9x Forward P/E, 33.5x Trailing P/E, 2.34x PEG, and 10.3x EV/Revenue (24.7% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRTX (20.8% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VRTX carries 115.6% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 28% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.